Immunogen Inc (IMGN)

6.53
0.04 0.61
NASDAQ : Health Care
Prev Close 6.57
Open 6.62
Day Low/High 6.44 / 6.63
52 Wk Low/High 2.68 / 18.78
Volume 2.35M
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 112.22M
Market Cap 758.61M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ImmunoGen Reaches Analyst Target Price

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $8.00, changing hands for $8.47/share.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632

First Week of April 2018 Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the April 2018 expiration.

ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference

ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston, chief financial officer, will present at the...

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

ImmunoGen Reports Recent Progress And Second Quarter 2017 Operating Results

ImmunoGen Reports Recent Progress And Second Quarter 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the quarter ended...

September 15th Options Now Available For ImmunoGen (IMGN)

September 15th Options Now Available For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options begin trading today, for the September 15th expiration.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

Short Interest In ImmunoGen Makes 10.6% Move

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,348,572 share increase in total short interest for ImmunoGen, Inc. , to 14,103,629, an increase of 10.57% since 05/31/2017.

ImmunoGen Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia

ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, presented data from the ongoing Phase 1 study evaluating single agent IMGN779 in patients with...

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $5.10, changing hands for $5.42/share.

First Week Of IMGN August 18th Options Trading

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the August 18th expiration.

ImmunoGen And Sanofi Amend License Agreements

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license...

ImmunoGen Announces Webcast Of Presentation At The Jefferies Global Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at...

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $5.10, changing hands for $5.40/share.

ImmunoGen Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced promising safety and efficacy data from monotherapy and combination...

ImmunoGen Reports Recent Progress And First Quarter 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the quarter ended...

ImmunoGen Announces Results From Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published In Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the results from a Phase 1 dose-escalation study evaluating...

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

Commit To Buy ImmunoGen At $2, Earn 9.6% Annualized Using Options

Investors eyeing a purchase of ImmunoGen, Inc. shares, but cautious about paying the going market price of $2.95/share, might benefit from considering selling puts among the alternative strategies at their disposal.

ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data from a mirvetuximab soravtansine (IMGN853) Phase 1 biopsy...

ImmunoGen Announces Presentations At AACR Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breath of the Company's expertise...

ImmunoGen Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the six-month period...

Short Interest Jumps 11.2% For IMGN

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,370,280 share increase in total short interest for ImmunoGen, Inc. , to 13,619,943, an increase of 11.19% since 01/13/2017.

TheStreet Quant Rating: E+ (Sell)